MedTrace Logo

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

NCT03040973 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2026-04-02

No results posted yet for this study

Summary

The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study

Conditions

  • Advanced Solid Tumors Which Are cMET-dependent

Interventions

DRUG

Capmatinib

Tablet for oral use; 150 mg, 200 mg; twice a day

DRUG

Nazartinib

Capsule for oral use; 25 mg, 50 mg; once a day

DRUG

Gefitinib

tablets for oral use; 250mg; once a day

DRUG

Osimertinib

Tablets for oral use; 40 mg, 80 mg; once a day.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-23
Primary Completion
2027-07-30
Completion
2027-07-30
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • China
  • Denmark
  • France
  • Germany
  • Italy
  • Singapore
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03040973 on ClinicalTrials.gov